CMS won't allow Part D formulary exclusion of protected drugs | Novartis CEO: New payment models needed for gene, cell therapies | B. Braun investing $1B in IV fluid manufacturing, distribution
May 20, 2019
Specialty Pharmacy SmartBrief
News for the specialty pharmacy industry
SIGN UP ⋅   FORWARD
Leading News
CMS won't allow Part D formulary exclusion of protected drugs
Medicare Part D plans will not be allowed to exclude drugs in protected classes from their formularies, and plans will be required to include information on lower-cost alternatives in monthly explanation of benefits reports sent to patients. Part D plans will be allowed to require prior authorization before covering some therapies.
CNBC (5/17) 
LinkedIn Twitter Facebook Email
Specialty Pharmacy Update
Novartis CEO: New payment models needed for gene, cell therapies
New pricing models are needed for expensive cell-based and gene therapies, which require only a short treatment period or even a single dose and thus do not lend themselves to the conventional pay-as-you-go model, writes Novartis CEO Vasant Narasimhan. Alternatives include installment models with clawback provisions, but current Medicare and Medicaid rules impede implementation, and new legislation is needed, Narasimhan writes.
CNBC (5/17) 
LinkedIn Twitter Facebook Email
B. Braun investing $1B in IV fluid manufacturing, distribution
B. Braun Medical has announced a $1 billion investment in IV fluid manufacturing facilities to help alleviate the shortage of IV fluids in the US. B. Braun's initiative, called Solutions for Life, will include the expansion of its Allentown, Pa., and Irvine, Calif., facilities, as well as expansions of two distribution facilities, and the construction of a distribution plant in Daytona Beach, Fla.
Becker's Hospital Review (5/15) 
LinkedIn Twitter Facebook Email
FDA OKs extended use of Takeda's Gattex
The FDA has approved Takeda Pharmaceutical's Gattex, or teduglutide, injection as a treatment for pediatric patients at least 1 year old with short bowel syndrome who need additional nutrition or fluids via intravenous feeding. The drug was previously approved for adult patients with SBS.
Pharmacy Times online (5/17) 
LinkedIn Twitter Facebook Email
Legislation & Regulation
Senate bill would address surprise billing through arbitration
A bill that supporters say would protect patients from unexpected out-of-network medical bills for emergency and non-emergency services was introduced by a bipartisan group of senators led by Sens. Bill Cassidy, R-La., and Maggie Hassan, D-N.H. The STOP Surprise Medical Bills Act would include an arbitration process and final payments would be based on "commercially-reasonable rates for that geographic area," according to Hassan's office.
Becker's Hospital CFO Report (5/17) 
LinkedIn Twitter Facebook Email
CMS postpones national coverage decision for CAR T-cell therapies
The CMS said Friday it would delay a final national coverage determination for chimeric antigen receptor T-cell therapies for cancer treatment such as Novartis' Kymriah and Gilead Sciences' Yescarta. The agency didn't give any reason for the delay in finalizing the proposal, released in February.
MedCity News (5/19),  Modern Healthcare (tiered subscription model) (5/17) 
LinkedIn Twitter Facebook Email
Clinical & Research News
Study identifies mechanism for drug resistance in lymphomas
Scientists from the Dana-Farber Cancer Institute and Moffitt Cancer Center studied how BCL2 inhibitor resistance evolves in B-cell lymphomas in response to venetoclax, or ABT-199, specifically in double-hit lymphoma and mantle cell lymphoma. The findings were reported in the journal Cancer Cell.
Genetic Engineering & Biotechnology News (5/16) 
LinkedIn Twitter Facebook Email
Study links industry payments to high prescribing of IBD drugs
Physicians who have a financial tie to makers of drugs for inflammatory bowel disease have a high likelihood of prescribing those drugs to Medicare beneficiaries, and the higher the industry payments, the higher the value of prescriptions written, according to an analysis presented at the Digestive Disease Week conference.
MedPage Today (free registration) (5/19) 
LinkedIn Twitter Facebook Email
Hot Topics
Trends & Technology
Report: Interoperability among factors that spoil EHR experience
Research published in the Journal of the American Medical Informatics Association cited slow progress on interoperability as one of seven factors related to poor physician experience with EHRs. Greater government regulation, obsolete servers and software, and training and implementation were also among the factors.
Becker's Health IT & CIO Report (5/15) 
LinkedIn Twitter Facebook Email
NASP News
Display images to show real-time content
Learn more about NASP:
Home page | Membership | News | Annual Meeting
  
  
If you only think about your own advancement, your own success, you run out of fuel pretty quickly. But if we believed in something bigger than ourselves, that kind of motivation is self-sustaining.
Elaine Chao,
US secretary of transportation

May is Asian/Pacific American Heritage Month

LinkedIn Twitter Facebook Email
  
  
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Partner Relations Manager  -  Molly Ufheil
Editor  -  Nicole Brown
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2019 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information